NCT06417762 Dime La VerDAD: Verify, Debunk, and Disseminate
| NCT ID | NCT06417762 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Influenza |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,400 participants |
| Start Date | 2024-07-02 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,400 participants in total. It began in 2024-07-02 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in favor of recommended immunizations in communities with high morbidity and mortality due to respiratory virus infections. Dime La Verdad is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers community health workers to disseminate reliable information about respiratory virus protection strategies through the use of personal narratives on social media. The proposed work will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in principles of health communication, 2) evaluate how diffusion of health messaging is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can encourage informed decision-making to promote evidence-based immunization practices and improve health outcomes.
Eligibility Criteria
Inclusion Criteria: 1. 18 years or older 2. Fluent in English or Spanish 3. Provide services as a community health worker or similar designation in at least one of the seven communities with high morbidity and mortality due to respiratory virus infections 4. Have a social media presence (personal or work related) Exclusion Criteria: 1. Plan to stop working as a community health worker or similar designation before spring of 2028 (end of data collection planned) 2. Do not wish to participate in a social media campaign
Contact & Investigator
Marina DelRios, MD
PRINCIPAL INVESTIGATOR
University of Chicago - Section of Emergency Medicine
Frequently Asked Questions
Who can join the NCT06417762 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Influenza. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06417762 currently recruiting?
Yes, NCT06417762 is actively recruiting participants. Contact the research team at Yajaira.BolanosFlores@bsd.uchicago.edu for enrollment information.
Where is the NCT06417762 trial being conducted?
This trial is being conducted at Chicago, United States, Chicago, United States, Iowa City, United States, Ann Arbor, United States.
Who is sponsoring the NCT06417762 clinical trial?
NCT06417762 is sponsored by University of Chicago. The principal investigator is Marina DelRios, MD at University of Chicago - Section of Emergency Medicine. The trial plans to enroll 1,400 participants.